Phibro Animal Health has delivered a very strong 149.1% return over the past 3 years, yet the current valuation checks paint a more mixed picture rather than a straightforward bargain or clear overpricing. Phibro Animal Health's 149.1% three year return shows shareholders have already seen very large gains, which raises the bar for any new buyers looking for further upside. Future expectations around margins and cash flow from its animal health portfolio can support today’s price. However,...

Phibro Animal Health (PAHC) is approaching a key disclosure date, with fourth quarter and full year 2026 results scheduled for release on August 26 after the market close, followed by a conference call on August 27. See our latest analysis for Phibro Animal Health. The upcoming earnings announcement comes after a mixed year for Phibro Animal Health, with the share price at US$35.44, a 1 month share price return of 7.23% and year to date share price return declining 4.99%, while the 3 year...

Phibro Animal Health's Animal Health growth and global reach support its outlook, but Brazil's antimicrobial transition and trade risks cloud near-term prospects.

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

Rockwell Medical (RMTI) delivered earnings and revenue surprises of -100.00% and -0.34%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Align Technology shares rise after Q2 earnings and revenues beat estimates, fueled by record Clear Aligner shipments and wider non-GAAP margins.

Tilray Brands (TLRY) delivered earnings and revenue surprises of -2,050.00% and +9.14%, respectively, for the quarter ended May 2026. Do the numbers hold clues to what lies ahead for the stock?

PAHC vs. SYK: Which Stock Is the Better Value Option?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Myriad Genetics expands its testing portfolio and advances its Cancer Care Continuum strategy. Can reimbursement risks and cost pressures temper growth?

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.